Total Payments
$29,611
2024 Payments
$1,427
Companies
39
Transactions
105
Medicare Patients
12,791
Medicare Billing
$3.9M
Payment Breakdown by Category
Consulting$15,505 (52.4%)
Research$10,613 (35.8%)
Food & Beverage$3,271 (11.0%)
Education$221.73 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,505 | 3 | 52.4% |
| Unspecified | $10,613 | 7 | 35.8% |
| Food and Beverage | $3,271 | 84 | 11.0% |
| Education | $221.73 | 11 | 0.7% |
Payments by Type
General
$18,997
98 transactions
Research
$10,613
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $12,619 | 10 | $0 (2024) |
| Clovis Oncology, Inc. | $10,749 | 9 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $2,122 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,406 | 3 | $0 (2024) |
| Medtronic, Inc. | $418.22 | 8 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $291.72 | 8 | $0 (2019) |
| ImmunoGen, Inc. | $277.73 | 3 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $149.00 | 4 | $0 (2024) |
| Amgen Inc. | $146.40 | 2 | $0 (2020) |
| Genentech USA, Inc. | $121.04 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,427 | 47 | Medtronic, Inc. ($418.22) |
| 2023 | $442.72 | 10 | ImmunoGen, Inc. ($277.73) |
| 2022 | $95.54 | 5 | Celgene Corporation ($26.42) |
| 2021 | $1,693 | 3 | AstraZeneca Pharmaceuticals LP ($1,681) |
| 2020 | $1,382 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,360) |
| 2019 | $697.83 | 15 | Pharmacyclics LLC, An AbbVie Company ($273.32) |
| 2018 | $1,282 | 9 | Clovis Oncology, Inc. ($956.25) |
| 2017 | $22,590 | 14 | PFIZER INC. ($12,515) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/12/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $24.04 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $45.73 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/25/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $16.75 | General |
| 10/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.67 | General |
| Category: Hematology | ||||||
| 10/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Genentech USA, Inc. | Itovebi (Biological), Tecentriq, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: BioOncology | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Medtronic, Inc. | KYPHON EXPRESS II KYPHOPAK TRAY (Device) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 10/09/2024 | Medtronic, Inc. | KYPHON EXPRESS II KYPHOPAK TRAY (Device) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 10/07/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $36.53 | General |
| Category: Oncology | ||||||
| 10/04/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Rare Disease | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Genentech USA, Inc. | Kadcyla (Biological), Phesgo | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: BioOncology | ||||||
| 08/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.45 | General |
| 08/19/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 08/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Oncology | ||||||
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $42.98 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2) | Clovis Oncology, Inc. | $9,782 | 6 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Clovis Oncology, Inc. | $831.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 68 | 3,595 | 110,485 | $3.8M | $694,765 |
| 2022 | 59 | 3,155 | 97,423 | $4.7M | $854,393 |
| 2021 | 63 | 3,049 | 108,710 | $5.3M | $1.2M |
| 2020 | 66 | 2,992 | 116,174 | $5.0M | $1.2M |
Total Patients
12,791
Total Services
432,792
Medicare Billing
$3.9M
Procedure Codes
256
All Medicare Procedures & Services
256 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 7,300 | $1.1M | $315,102 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 4,320 | $300,240 | $75,983 | 25.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 110 | 480 | $329,280 | $51,098 | 15.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 290 | 440 | $65,120 | $28,422 | 43.6% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 13 | 324 | $284,796 | $26,678 | 9.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 337 | $69,085 | $20,105 | 29.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 339 | 1,779 | $33,801 | $14,902 | 44.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 84 | 257 | $78,128 | $12,644 | 16.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $32,928 | $11,890 | 36.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 235 | 1,162 | $72,044 | $11,842 | 16.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 301 | 1,553 | $54,355 | $11,722 | 21.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 24 | 110 | $7,700 | $8,163 | 106.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 15 | 62 | $61,132 | $7,983 | 13.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 84 | 289 | $43,928 | $6,588 | 15.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 16,320 | $97,920 | $6,339 | 6.5% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 68 | 312 | $29,952 | $5,780 | 19.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 81 | 404 | $42,420 | $4,973 | 11.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 37 | 87 | $29,058 | $4,614 | 15.9% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 19 | 24,780 | $49,560 | $4,142 | 8.4% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 63 | 440 | $23,760 | $4,010 | 16.9% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 42 | 187 | $23,188 | $3,813 | 16.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 109 | 284 | $16,472 | $3,783 | 23.0% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 40 | 104 | $14,456 | $3,610 | 25.0% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 56 | 141 | $21,855 | $3,086 | 14.1% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 52 | 163 | $9,780 | $2,758 | 28.2% |
About Dr. Ling Ma, MD
Dr. Ling Ma, MD is a Hematology & Oncology healthcare provider based in Lakewood, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063617454.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ling Ma, MD has received a total of $29,611 in payments from pharmaceutical and medical device companies, with $1,427 received in 2024. These payments were reported across 105 transactions from 39 companies. The most common payment nature is "Consulting Fee" ($15,505).
As a Medicare-enrolled provider, Ma has provided services to 12,791 Medicare beneficiaries, totaling 432,792 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 256 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Lakewood, CO
- Active Since 06/18/2007
- Last Updated 03/03/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063617454
Products in Payments
- XTANDI (Drug) $12,480
- RUBRACA (Drug) $9,782
- LYNPARZA (Drug) $1,700
- PIQRAY (Drug) $1,360
- Rubraca (Drug) $966.43
- OSTEOCOOL RF ABLATION SYSTEM (Device) $385.29
- Imbruvica (Drug) $291.72
- Elahere (Biological) $277.73
- Nerlynx (Drug) $132.25
- Kyprolis (Biological) $124.32
- ZEJULA (Drug) $109.36
- TAGRISSO (Drug) $91.54
- IMFINZI (Drug) $87.04
- FOUNDATIONONE (Device) $84.14
- SOMATULINE DEPOT (Drug) $82.85
- REBLOZYL (Biological) $81.02
- PADCEV (Biological) $79.13
- Yescarta (Drug) $71.12
- ENHERTU (Biological) $69.06
- SOLIRIS (Drug) $59.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lakewood
Dr. Nauman Moazzam, Md, MD
Hematology & Oncology — Payments: $91,446
Hematology & Oncology $91,446
Eric Cheung, D.o, D.O
Hematology & Oncology — Payments: $41,197
Hematology & Oncology $41,197
Raghu Nandan, M.d, M.D
Hematology & Oncology — Payments: $9,228
Hematology & Oncology $9,228
Stephen Frank, Md, MD
Hematology & Oncology — Payments: $284.78
Hematology & Oncology $284.78
Sultanali Alidina, M.d, M.D
Hematology & Oncology — Payments: $13.71
Hematology & Oncology $13.71
Dr. Joseph Napoli, M.d, M.D
Hematology & Oncology
Hematology & Oncology